Skip to main content
main-content

Axel S Merseburger

Prof. Dr. med. Axel S. Merseburger is the chairman of the Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School in 2002 after a one-year academic research programme in Washington DC, USA, where he completed his MD thesis. In 2008, he accepted a staff position in Hannover and was promoted to associate professor in 2009; he obtained full professorship in 2012.

Professor Merseburger is board certified in urology and is a member of numerous national and international urological and oncological associations. In addition to serving as a reviewer and member of the editorial board of many journals, Professor Merseburger is the associate editor of the World Journal of Urology and Editor-in-Chief of the “Advanced Prostate Cancer Resource Centre”. Furthermore, he is a member of the European Association of Urology (EAU) Guideline Groups on Renal Cell Cancer. He serves as national and international principal investigator in several phase II/III clinical trials.

Professor Merseburger has won multiple awards, stipends and prizes for his molecular and clinical research and has authored and co-authored more that 200 publications.

Latest contributions from Axel Merseburger

02-10-2019 | Genitourinary cancers | Video | Article

Expert highlights: Genitourinary cancers at ESMO 2019

Axel Merseburger takes us through his top picks of the genitourinary cancer research reported at the ESMO Congress 2019, including updates on the TITAN and STAMPEDE prostate cancer trials, the SORCE trial in renal cell carcinoma, and the investigation of first-line enfortumab vedotin in bladder cancer (5:33).

01-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | Article

Researcher comment: Apalutamide addition improves metastatic CSPC survival

Study author Axel Merseburger takes us through the TITAN trial investigating the addition of apalutamide to androgen deprivation therapy in the metastatic castration-sensitive prostate cancer setting, and also addresses the key question of how physicians should choose between the available treatment options (3:03).

16-03-2018 | Axel S Merseburger | Article

Advisory board comment

Comment on: EBRT plus brachytherapy stands out for high-risk prostate cancer

28-04-2017 | Genitourinary cancers | Conference report | Article

Highlights from the 2017 Genitourinary Cancer Symposium (ASCO-GU), Orlando, Florida, USA

Advisory Board member Prof Axel Merseburger discusses the key outcomes from the 2017 ASCO-GU Congress in Orlando, Florida.